A detailed history of Neo Ivy Capital Management transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Neo Ivy Capital Management holds 4,902 shares of CRL stock, worth $801,477. This represents 0.33% of its overall portfolio holdings.

Number of Shares
4,902
Holding current value
$801,477
% of portfolio
0.33%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$187.96 - $245.29 $921,379 - $1.2 Million
4,902 New
4,902 $965,000
Q3 2023

Nov 29, 2023

BUY
$194.44 - $217.61 $214,661 - $240,241
1,104 New
1,104 $216,000
Q4 2022

Mar 24, 2023

BUY
$197.11 - $250.07 $421,026 - $534,149
2,136 New
2,136 $465,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $8.32B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Neo Ivy Capital Management Portfolio

Follow Neo Ivy Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.